Westerlin Drugs Profile
Key Indicators
- Authorised Capital ₹ 5.00 M
as on 03-07-2024
- Paid Up Capital ₹ 0.12 M
as on 03-07-2024
- Company Age 34 Year,
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 7.40 M
as on 03-07-2024
- Revenue 41.91%
(FY 2023)
- Profit -394.75%
(FY 2023)
- Ebitda 34.08%
(FY 2023)
- Net Worth -69.79%
(FY 2023)
- Total Assets 6.09%
(FY 2023)
About Westerlin Drugs
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 5.00 M and a paid-up capital of Rs 0.12 M.
The company currently has active open charges totaling ₹7.40 M.
Sunil Kumar, Subhash Singh, and Lakshmi Jha serve as directors at the Company.
- CIN/LLPIN
U00304BR1990PTC004286
- Company No.
004286
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
28 Dec 1990
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Patna
Industry
Company Details
- Location
Patna, Bihar, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Westerlin Drugs Private Limited offer?
Westerlin Drugs Private Limited offers a wide range of products and services, including Anti Infective Drugs & Medicines, Antibiotic Tablets, Capsule & Syrup, Cardiovascular Drugs & Medication, Cholesterol Medicine, Antiparasitic Drug, Nutraceuticals & Dietary Supplements, Multivitamin Syrup & Drops, Digestive System Drugs & Medicines, Antacid Drugs, Antibacterial Drugs.
Who are the key members and board of directors at Westerlin Drugs?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sunil Kumar  | Director | 01-Oct-2015 | Current |
| Subhash Singh | Director | 01-Oct-2015 | Current |
| Lakshmi Jha | Director | 15-Dec-2022 | Current |
Financial Performance of Westerlin Drugs.
Westerlin Drugs Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 41.91% increase. The company also saw a substantial fall in profitability, with a 394.75% decrease in profit. The company's net worth observed a substantial decline by a decrease of 69.79%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Westerlin Drugs?
In 2023, Westerlin Drugs had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Saroj Mother & Child Care Centre Private LimitedActive 17 years 8 monthsSunil Kumar, Subhash Singh and 1 more are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
State Bank Of India Creation Date: 20 Oct 2022 | ₹7.40 M | Open |
How Many Employees Work at Westerlin Drugs?
Unlock and access historical data on people associated with Westerlin Drugs, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Westerlin Drugs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Westerlin Drugs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
